Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Star Imaging And Path LabBOM:544482 -2.22%21 Return-on-Tangible-Equity is 16.56% as of Mar. 2026, which is 52% below its 10-year median of 34.28. GuruFocus rates BOM:544482 with a GF Score™ of 21/100. Among 190 Medical Diagnostics & Research companies, Star Imaging And Path Lab ranks better than 74.74% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Star Imaging And Path Lab's annualized net income for the quarter that ended in Mar. 2026 was ₹184.6 Mil. Star Imaging And Path Lab's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹1,114.9 Mil. Therefore, Star Imaging And Path Lab's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 16.56%.
The historical rank and industry rank for Star Imaging And Path Lab's Return-on-Tangible-Equity or its related term are showing as below:
BOM:544482'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 3.22 Med: 34.28 Max: 52.18
Current: 21.47
During the past 5 years, Star Imaging And Path Lab's highest Return-on-Tangible-Equity was 52.18%. The lowest was 3.22%. And the median was 34.28%.
BOM:544482's Return-on-Tangible-Equity is ranked better than 74.74% of 190
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.32
vs BOM:544482: 21.47
Star Imaging And Path Lab (BOM:544482) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Star Imaging And Path Lab Return-on-Tangible-Equity Related Terms
Star Imaging And Path Lab Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Star Imaging And Path Lab's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Star Imaging And Path Lab Return-on-Tangible-Equity Chart
BOM:544482 vs TMO, DHR, IDXX: Return-on-Tangible-Equity Comparison
For the Diagnostics & Research subindustry, Star Imaging And Path Lab's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Star Imaging And Path Lab Return-on-Tangible-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Star Imaging And Path Lab's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Star Imaging And Path Lab's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 16.56% mean?
Star Imaging And Path Lab (BOM:544482) has a Return-on-Tangible-Equity of 16.56% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Star Imaging And Path Lab and its competitors. This is 52% below median its historical median of 34.28. Over the past decade, Star Imaging And Path Lab's Return-on-Tangible-Equity has ranged from 3.22 to 52.18. According to the industry distribution chart, Star Imaging And Path Lab ranks #48 out of 190 companies in the Medical Diagnostics & Research industry, placing it in the top 25.3%.
Is Star Imaging And Path Lab's Return-on-Tangible-Equity too high?
Star Imaging And Path Lab's current Return-on-Tangible-Equity of 16.56% is 52% below median its 10-year median of 34.28. Over the past 10 years, this metric has ranged from a low of 3.22 to a high of 52.18. The Medical Diagnostics & Research industry median Return-on-Tangible-Equity is 0.32. Star Imaging And Path Lab's value of 16.56% is 5075% above this industry median. Based on the distribution chart, Star Imaging And Path Lab ranks #48 out of 190 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Star Imaging And Path Lab has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Star Imaging And Path Lab's Return-on-Tangible-Equity compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Star Imaging And Path Lab ranks #48 out of 190 companies for Return-on-Tangible-Equity. This puts Star Imaging And Path Lab in the upper half of its industry. The industry median Return-on-Tangible-Equity is 0.32. Star Imaging And Path Lab's value of 16.56% is 5075% above this benchmark. Historically, Star Imaging And Path Lab's own Return-on-Tangible-Equity has ranged from 3.22 to 52.18 over the past decade. While the company's 10-year median is 34.28 vs. the industry median of 0.32, Star Imaging And Path Lab has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Diagnostics & Research company?
The median Return-on-Tangible-Equity among Medical Diagnostics & Research companies is 0.32, based on 190 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Star Imaging And Path Lab's current Return-on-Tangible-Equity of 16.56% is 5075% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Star Imaging And Path Lab and its competitors. For the Medical Diagnostics & Research industry, the median Return-on-Tangible-Equity is 0.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Star Imaging And Path Lab's current Return-on-Tangible-Equity is 16.56%, which is 52% below median its own 10-year median of 34.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Star Imaging And Path Lab stock overvalued right now?
Star Imaging And Path Lab (BOM:544482) has a current Return-on-Tangible-Equity of 16.56%. The current Return-on-Tangible-Equity is 16.56%, which is 52% below median its 10-year median of 34.28 and 5075% above the Medical Diagnostics & Research industry median of 0.32. Star Imaging And Path Lab's overall GF Score™ is 21/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Star Imaging And Path Lab (BOM:544482), the current Return-on-Tangible-Equity is 16.56% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Star Imaging And Path Lab Ltd operates a diagnostic testing network, NABL accredited, delivering pathology, radiology, Cardiology, and Neurology services in Delhi and Uttar Pradesh. It offers a comprehensive range of diagnostic imaging services and clinical laboratory tests, including both routine and specialized studies and profiles. These services are essential for the prediction, early detection, diagnostic screening, confirmation, and monitoring of diseases. The company's diagnostic imaging and radiology services encompass X-rays, computed tomography (CT) scans, magnetic resonance imaging (MRI) scans, ultrasounds, bone mineral densitometry, and mammography.
21GF Score
Get the complete analysis for BOM:544482
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544482 has been successfully added to your 
